Cannabinoides Concentrations and Hyperemesis Syndrom Occurrence in Regular Cannabis Consumer (CANEMESE)

Poitiers University Hospital200 enrolled

Overview

The Cannabinoide Hyperemesis Syndrom (CHS) is defined as a recurrent syndrome of intractable vomiting that occurs in chronic cannabis consumers. The diagnosis is linked to clinical criteria only. The physiopathology of CHS is unknown and we observe an increase of cases with this syndrom since 2016 (Schreck et al., 2018). The aim of this study is to investigate the involvement of exogenous cannabinoids concentrations in chronic cannabis users in the occurrence of CHS.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

200

Conditions

Chronic Consumption of Cannabis

Interventions

1 blood samplePROCEDURE

2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects without protection by a legal regime (guardianship, trusteeship) * Subjects affiliated to an appropriate social security system * Subjects must sign an informed consent form Inclusion Criteria for Group 1: \- Subjects must have the CHS diagnosis confirmed Inclusion Criteria for Group 2: \- Subjects must be chronic cannabis consumers and never had CHS Exclusion Criteria: * Subjects must not have addictive comorbidities or psychoactive substance abuse (except alcohol and tabacco)

Locations (1)

CHU

Poitiers, France

RECRUITING

Outcomes

Primary Outcomes

involvement of exogenous cannabinoids concentrations in chronic cannabis users in the occurrence of CHS (see details below for exogenous cannabinoids)